Skip to main content
menu
URochester Medicine / Center for Health + Technology / Our Expertise / CHeT Outcomes / NDD-HI: Neurodevelopmental Disorders Health Index

NDD-HI 0+ & NDD-HI 2+: Neurodevelopmental Disorders Health Index (ObsRO)

Our NDD-HI 0+ & NDD-HI 2+: Neurodevelopmental Disorders Health Index is an observer-reported outcome (ObsRO) designed for use when patient self-report is not feasible. It captures caregiver and observer perspectives on observable signs, behaviors, and functional impact, contributing valuable data to clinical research and trials.

  • Type of Clinical Outcome Assessment (COA): Caregiver or observer-reported outcome measure (CRO/ObsRO)
  • Administration Mode: Self-administered
  • Therapeutic Area: Neurodevelopmental Disorders
  • Approximate Completion Time: NDD-HI 0+ <2 minutes; NDD-HI 2+ <7 minutes 
  • Required Supervision: None
  • Recall Period: Immediate point in time

Instrument Variations

For ages 0 and older:

  • The Neurodevelopmental Disorders - Health Index (NDD-HI) 0+
    • Completion Time: <2 minutes (completed by a caregiver on behalf of a patient)
  • The Neurodevelopmental Disorders - Health Index Short Form (NDD-HI-SF) 0+
    • Completion Times: <1 minute (completed by a caregiver on behalf of a patient)

For ages 2 and older:

  • The Neurodevelopmental Disorders - Health Index (NDD-HI) 2+
    • Completion Times: <7 minutes (completed by a caregiver on behalf of a patient)
  • The Neurodevelopmental Disorders - Health Index Short Form (NDD-HI-SF) 2+
    • Completion Times: <1 minute (completed by a caregiver on behalf of a patient)

Symptom Subscales

  • NDD-HI 0+ Number of Independently Validated Symptom Subscales:12
    • Behavioral Issues; Muscle Weakness; Problems Using their Hands, Fingers, or Arms; Emotional Issues; Trouble Sleeping or Daytime Sleepiness; Appearing Drained or Tired; Pain; Choking or Swallowing Issues; Gastrointestinal (Stomach) Issues; Breathing Difficulties; Seizures; Abnormal Movements
  • NDD-HI 2+ Number of Independently Validated Symptom Subscales:17
    • Behavioral Issues; Muscle Weakness; Problems Using their Hands, Fingers, or Arms; Emotional Issues; Difficulty Thinking; Trouble Sleeping or Daytime Sleepiness; Inability to do Activities; Appearing Drained or Tired; Pain; Choking or Swallowing Issues; Gastrointestinal (Stomach) Issues; Difficulty Communicating; Breathing Difficulties; Seizures; Abnormal Movements; Impaired Social Interactions; Hip, Thigh, or Knee Weakness

Instrument Attributes

  • The NDD-HI 0+ and NDD-HI 2+ are caregiver-reported outcome (CRO/ObsRO) measures designed to assess symptoms and health-related quality-of-life from the perspective of caregivers of individuals with neurodevelopmental disorders ages 0 and older, and ages 2 and older respectively.
  • Designed and validated to fully satisfy regulatory and published FDA guidance for use in drug-labeling claims and measuring changes in how a patient feels and functions.
  • The NDD-HI 0+ and NDD-HI 2+ were developed using extensive caregiver input, including an analysis of 16,021 caregiver quotes and a large cross-sectional study involving 404 caregivers.
  • The NDD-HI 0+ and NDD-HI 2+ are highly relevant to patients, has low participant burden, and correlates with markers of disease severity.
  • Utilized in industry sponsored clinical trials.
  • eCOA Implementation Guide available.
  • English (US)

Additional translations available upon request.

Pending

Presentations coming soon.

This list includes studies made available to the public on ClinicalTrials.gov. Please note that this list does not fully cover academic and industry studies that use Health Indexes.

NCT Number - NCT07569445
Study Title - Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome
Study URL - https://clinicaltrials.gov/study/NCT07569445
Condition - Rett Syndrome
Sponsor - University of Rochester
Intervention - Procedure: Electroencephalogram (EEG) Recording

Instrument Scoring

The NDD-HI 0+ and NDD-HI 2+ symptom questions within each subscale are weighted based on participant-reported prevalence and average impact as identified through the cross-sectional study. In addition to scoring utilizing aggregate NDD-HI reported prevalence and average impact, the NDD-HI may alternatively be scored using data specific to Fragile X, SHANK3, SYNGAP1, SCN2A, or SMS populations. All subscales are scored on a scale of 0 to 100 with 0 representing no disease burden and 100 representing the maximum level of disease burden. Subscale scores are also weighted to generate a total NDD-HI score (0-100) representing overall disease burden.

Inquire about Licensing   View All Instruments